Abstract
References
- 1.Salazar CA, Isaacson KB. Office OperativeHysteroscopy: An Update. J Minim Invasive Gynecol.2018; 25: 199-208.
- 2.Amer-Cuenca JJ, Marín-Buck A, Vitale SG, et al.Non-pharmacological pain control in outpatienthysteroscopies. Minim Invasive Ther Allied Technol.2020; 29: 10-9.
- 3.Paulo AAS, Solheiro MHR, Paulo COS, Afreixo VMA. What proportion of women refers moderate tosevere pain during office hysteroscopy with a mini-hysteroscope? A systematic review and meta-analysis. Arch Gynecol Obstet. 2016; 293: 37-46.
- 4.Abis P, Bigozzi MA, Dotto J, et al. Pain ManagementDuring Office Hysteroscopy: A Survey ofHysteroscopists. Surg Technol Int. 2020; 37: 161-6.
Effect of misoprostol on cervical transition pain in office hysteroscopy: Results of a tertiary center
Abstract
Objective: Office hysteroscopy is a method that has become increasingly popular because of its low complication rate, rapid recovery, and cost-effectiveness. Pain is the biggest obstacle to the successful completion of office hysteroscopy procedures. Thus, the present study aimed to investigate the efficacy of misoprostol in providing cervical ripening, and thus reducing pain during the cervical transition of hysteroscopy.
Methods: This research was conducted as an observational case-control study. Seventy-nine patients who underwent office hysteroscopy were included. Twenty-nine patients were administered 200 μg of vaginal misoprostol 4 h before office hysteroscopy, whereas the control group consisting of 50 patients was not provided with premedication for cervical dilatation. Patients were asked to rate their pain between 0 and 10 using the visual analog scale (VAS) 30 min after the procedure.
Results: VAS pain scores after diagnostic office hysteroscopy (3.61 ± 0.61) and operative office hysteroscopy (4.45 ± 0.82) were significantly lower in the misoprostol group than in the control group patients. None of the patients experienced serious side effects caused by misoprostol and requested to end the procedure.
Conclusion: A significant reduction in the VAS pain score was detected in patients who were administered 200 μg of vaginal misoprostol 4 h before office hysteroscopy. Misoprostol facilitated transition by providing cervical maturation and reduced the risk of pain-related unsuccessful hysteroscopy.
References
- 1.Salazar CA, Isaacson KB. Office OperativeHysteroscopy: An Update. J Minim Invasive Gynecol.2018; 25: 199-208.
- 2.Amer-Cuenca JJ, Marín-Buck A, Vitale SG, et al.Non-pharmacological pain control in outpatienthysteroscopies. Minim Invasive Ther Allied Technol.2020; 29: 10-9.
- 3.Paulo AAS, Solheiro MHR, Paulo COS, Afreixo VMA. What proportion of women refers moderate tosevere pain during office hysteroscopy with a mini-hysteroscope? A systematic review and meta-analysis. Arch Gynecol Obstet. 2016; 293: 37-46.
- 4.Abis P, Bigozzi MA, Dotto J, et al. Pain ManagementDuring Office Hysteroscopy: A Survey ofHysteroscopists. Surg Technol Int. 2020; 37: 161-6.
Details
| Primary Language | English |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Original Articles |
| Authors | |
| Publication Date | September 2, 2022 |
| Submission Date | June 13, 2022 |
| Published in Issue | Year 2022 Volume: 49 Issue: 3 |